EMA Updates Guidance on Risk Management Plans for COVID-19 Vaccines
Guidance published during the pandemic has been updated to include content requirements for summary safety reports.
The European Medicines Agency’s (EMA’s) Pharmacovigilance Risk Assessment Committee (PRAC) announced on Feb. 11, 2022 the adoption of updated guidance on core requirements for risk management plans of COVID-19 vaccines. Guidance published during the pandemic has been updated to include content requirements for summary safety reports to be submitted to the agency and details on safety topics where monitoring with periodic safety update reports is more appropriate. The updated guidance also includes considerations for frequency changes for summary safety reports and when it is appropriate to no longer submit safety reports.
The updates were made after discussion at PRAC and experience gathered during the pandemic. The revised guidance can be found on EMA’s website.
Source: EMA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
